Literature DB >> 30624711

Using germline variants to estimate glioma and subtype risks.

Jeanette E Eckel-Passow1, Paul A Decker1, Matt L Kosel1, Thomas M Kollmeyer2, Annette M Molinaro3,4, Terri Rice3, Alissa A Caron2, Kristen L Drucker2, Corinne E Praska2, Melike Pekmezci5, Helen M Hansen3, Lucie S McCoy3, Paige M Bracci4, Bradley J Erickson6, Claudia F Lucchinetti7, Joseph L Wiemels8, John K Wiencke3,4,9, Melissa L Bondy10, Beatrice Melin11, Terry C Burns12, Caterina Giannini2, Daniel H Lachance2,7, Margaret R Wrensch3,4,9, Robert B Jenkins2.   

Abstract

BACKGROUND: Twenty-five single nucleotide polymorphisms (SNPs) are associated with adult diffuse glioma risk. We hypothesized that the inclusion of these 25 SNPs with age at diagnosis and sex could estimate risk of glioma as well as identify glioma subtypes.
METHODS: Case-control design and multinomial logistic regression were used to develop models to estimate the risk of glioma development while accounting for histologic and molecular subtypes. Case-case design and logistic regression were used to develop models to predict isocitrate dehydrogenase (IDH) mutation status. A total of 1273 glioma cases and 443 controls from Mayo Clinic were used in the discovery set, and 852 glioma cases and 231 controls from UCSF were used in the validation set. All samples were genotyped using a custom Illumina OncoArray.
RESULTS: Patients in the highest 5% of the risk score had more than a 14-fold increase in relative risk of developing an IDH mutant glioma. Large differences in lifetime absolute risk were observed at the extremes of the risk score percentile. For both IDH mutant 1p/19q non-codeleted glioma and IDH mutant 1p/19q codeleted glioma, the lifetime risk increased from almost null to 2.3% and almost null to 1.7%, respectively. The SNP-based model that predicted IDH mutation status had a validation concordance index of 0.85.
CONCLUSIONS: These results suggest that germline genotyping can provide new tools for the initial management of newly discovered brain lesions. Given the low lifetime risk of glioma, risk scores will not be useful for population screening; however, they may be useful in certain clinically defined high-risk groups.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  classification; genotype; glioblastoma; glioma; polygenic

Mesh:

Year:  2019        PMID: 30624711      PMCID: PMC6422428          DOI: 10.1093/neuonc/noz009

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  47 in total

1.  Reproductive factors and hormone use and risk of adult gliomas.

Authors:  Martha J Felini; Andrew F Olshan; Jane C Schroeder; Susan E Carozza; Rei Miike; Terri Rice; Margaret Wrensch
Journal:  Cancer Causes Control       Date:  2008-09-03       Impact factor: 2.506

2.  Genome-wide association study identifies five susceptibility loci for glioma.

Authors:  Sanjay Shete; Fay J Hosking; Lindsay B Robertson; Sara E Dobbins; Marc Sanson; Beatrice Malmer; Matthias Simon; Yannick Marie; Blandine Boisselier; Jean-Yves Delattre; Khe Hoang-Xuan; Soufiane El Hallani; Ahmed Idbaih; Diana Zelenika; Ulrika Andersson; Roger Henriksson; A Tommy Bergenheim; Maria Feychting; Stefan Lönn; Anders Ahlbom; Johannes Schramm; Michael Linnebank; Kari Hemminki; Rajiv Kumar; Sarah J Hepworth; Amy Price; Georgina Armstrong; Yanhong Liu; Xiangjun Gu; Robert Yu; Ching Lau; Minouk Schoemaker; Kenneth Muir; Anthony Swerdlow; Mark Lathrop; Melissa Bondy; Richard S Houlston
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

3.  Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.

Authors:  X Lin; M Lee; O Buck; K M Woo; Z Zhang; V Hatzoglou; A Omuro; J Arevalo-Perez; A A Thomas; J Huse; K Peck; A I Holodny; R J Young
Journal:  AJNR Am J Neuroradiol       Date:  2016-12-08       Impact factor: 3.825

4.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Authors:  Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 176.079

5.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

6.  Prediction of breast cancer risk based on profiling with common genetic variants.

Authors:  Nasim Mavaddat; Paul D P Pharoah; Kyriaki Michailidou; Jonathan Tyrer; Mark N Brook; Manjeet K Bolla; Qin Wang; Joe Dennis; Alison M Dunning; Mitul Shah; Robert Luben; Judith Brown; Stig E Bojesen; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Kamila Czene; Hatef Darabi; Mikael Eriksson; Julian Peto; Isabel Dos-Santos-Silva; Frank Dudbridge; Nichola Johnson; Marjanka K Schmidt; Annegien Broeks; Senno Verhoef; Emiel J Rutgers; Anthony Swerdlow; Alan Ashworth; Nick Orr; Minouk J Schoemaker; Jonine Figueroa; Stephen J Chanock; Louise Brinton; Jolanta Lissowska; Fergus J Couch; Janet E Olson; Celine Vachon; Vernon S Pankratz; Diether Lambrechts; Hans Wildiers; Chantal Van Ongeval; Erik van Limbergen; Vessela Kristensen; Grethe Grenaker Alnæs; Silje Nord; Anne-Lise Borresen-Dale; Heli Nevanlinna; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Jenny Chang-Claude; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Peter A Fasching; Lothar Haeberle; Arif B Ekici; Matthias W Beckmann; Barbara Burwinkel; Frederik Marme; Andreas Schneeweiss; Christof Sohn; Amy Trentham-Dietz; Polly Newcomb; Linda Titus; Kathleen M Egan; David J Hunter; Sara Lindstrom; Rulla M Tamimi; Peter Kraft; Nazneen Rahman; Clare Turnbull; Anthony Renwick; Sheila Seal; Jingmei Li; Jianjun Liu; Keith Humphreys; Javier Benitez; M Pilar Zamora; Jose Ignacio Arias Perez; Primitiva Menéndez; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Natalia V Bogdanova; Natalia N Antonenkova; Thilo Dörk; Hoda Anton-Culver; Susan L Neuhausen; Argyrios Ziogas; Leslie Bernstein; Peter Devilee; Robert A E M Tollenaar; Caroline Seynaeve; Christi J van Asperen; Angela Cox; Simon S Cross; Malcolm W R Reed; Elza Khusnutdinova; Marina Bermisheva; Darya Prokofyeva; Zalina Takhirova; Alfons Meindl; Rita K Schmutzler; Christian Sutter; Rongxi Yang; Peter Schürmann; Michael Bremer; Hans Christiansen; Tjoung-Won Park-Simon; Peter Hillemanns; Pascal Guénel; Thérèse Truong; Florence Menegaux; Marie Sanchez; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Valeria Pensotti; John L Hopper; Helen Tsimiklis; Carmel Apicella; Melissa C Southey; Hiltrud Brauch; Thomas Brüning; Yon-Dschun Ko; Alice J Sigurdson; Michele M Doody; Ute Hamann; Diana Torres; Hans-Ulrich Ulmer; Asta Försti; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Irene L Andrulis; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Georgia Chenevix-Trench; Rosemary Balleine; Graham G Giles; Roger L Milne; Catriona McLean; Annika Lindblom; Sara Margolin; Christopher A Haiman; Brian E Henderson; Fredrick Schumacher; Loic Le Marchand; Ursula Eilber; Shan Wang-Gohrke; Maartje J Hooning; Antoinette Hollestelle; Ans M W van den Ouweland; Linetta B Koppert; Jane Carpenter; Christine Clarke; Rodney Scott; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Hermann Brenner; Volker Arndt; Christa Stegmaier; Aida Karina Dieffenbach; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Kenneth Offit; Joseph Vijai; Mark Robson; Rohini Rau-Murthy; Miriam Dwek; Ruth Swann; Katherine Annie Perkins; Mark S Goldberg; France Labrèche; Martine Dumont; Diana M Eccles; William J Tapper; Sajjad Rafiq; Esther M John; Alice S Whittemore; Susan Slager; Drakoulis Yannoukakos; Amanda E Toland; Song Yao; Wei Zheng; Sandra L Halverson; Anna González-Neira; Guillermo Pita; M Rosario Alonso; Nuria Álvarez; Daniel Herrero; Daniel C Tessier; Daniel Vincent; Francois Bacot; Craig Luccarini; Caroline Baynes; Shahana Ahmed; Mel Maranian; Catherine S Healey; Jacques Simard; Per Hall; Douglas F Easton; Montserrat Garcia-Closas
Journal:  J Natl Cancer Inst       Date:  2015-04-08       Impact factor: 13.506

7.  Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.

Authors:  Karim Labreche; Ben Kinnersley; Giulia Berzero; Anna Luisa Di Stefano; Amithys Rahimian; Ines Detrait; Yannick Marie; Benjamin Grenier-Boley; Khe Hoang-Xuan; Jean-Yves Delattre; Ahmed Idbaih; Richard S Houlston; Marc Sanson
Journal:  Acta Neuropathol       Date:  2018-02-19       Impact factor: 17.088

8.  Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.

Authors:  Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

9.  IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Authors:  Heather E Leeper; Alissa A Caron; Paul A Decker; Robert B Jenkins; Daniel H Lachance; Caterina Giannini
Journal:  Oncotarget       Date:  2015-10-06

10.  Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-Searching for a practical approach.

Authors:  Małgorzata Neska-Matuszewska; Joanna Bladowska; Marek Sąsiadek; Anna Zimny
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240

View more
  9 in total

Review 1.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

2.  Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C.

Authors:  Jeanette E Eckel-Passow; Kristen L Drucker; Thomas M Kollmeyer; Matt L Kosel; Paul A Decker; Annette M Molinaro; Terri Rice; Corinne E Praska; Lauren Clark; Alissa Caron; Alexej Abyzov; Anthony Batzler; Jun S Song; Melike Pekmezci; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Joseph Wiemels; John K Wiencke; Stephen Francis; Terry C Burns; Caterina Giannini; Daniel H Lachance; Margaret Wrensch; Robert B Jenkins
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

Review 3.  Inherited genetics of adult diffuse glioma and polygenic risk scores-a review.

Authors:  Jeanette E Eckel-Passow; Daniel H Lachance; Paul A Decker; Thomas M Kollmeyer; Matthew L Kosel; Kristen L Drucker; Susan Slager; Margaret Wrensch; W Oliver Tobin; Robert B Jenkins
Journal:  Neurooncol Pract       Date:  2022-03-12

4.  Random effect based tests for multinomial logistic regression in genetic association studies.

Authors:  Qianchuan He; Yang Liu; Meiling Liu; Michael C Wu; Li Hsu
Journal:  Genet Epidemiol       Date:  2021-08-17       Impact factor: 2.344

5.  Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.

Authors:  Mohith Manjunath; Jialu Yan; Yeoan Youn; Kristen L Drucker; Thomas M Kollmeyer; Andrew M McKinney; Valter Zazubovich; Yi Zhang; Joseph F Costello; Jeanette Eckel-Passow; Paul R Selvin; Robert B Jenkins; Jun S Song
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

Review 6.  The Genetic Architecture of Gliomagenesis-Genetic Risk Variants Linked to Specific Molecular Subtypes.

Authors:  Wendy Yi-Ying Wu; Gunnar Johansson; Carl Wibom; Thomas Brännström; Annika Malmström; Roger Henriksson; Irina Golovleva; Melissa L Bondy; Ulrika Andersson; Anna M Dahlin; Beatrice Melin
Journal:  Cancers (Basel)       Date:  2019-12-12       Impact factor: 6.639

Review 7.  Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science.

Authors:  Linda Ding; Carla Bradford; I-Lin Kuo; Yankhua Fan; Kenneth Ulin; Abdulnasser Khalifeh; Suhong Yu; Fenghong Liu; Jonathan Saleeby; Harry Bushe; Koren Smith; Camelia Bianciu; Salvatore LaRosa; Fred Prior; Joel Saltz; Ashish Sharma; Mark Smyczynski; Maryann Bishop-Jodoin; Fran Laurie; Matthew Iandoli; Janaki Moni; M Giulia Cicchetti; Thomas J FitzGerald
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

Review 8.  Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era.

Authors:  Eduard Porta-Pardo; Alfonso Valencia; Adam Godzik
Journal:  FEBS Lett       Date:  2020-04-28       Impact factor: 4.124

9.  Glioma: interaction of acquired and germline genetics.

Authors:  Jeanette E Eckel-Passow; Daniel H Lachance; Robert B Jenkins
Journal:  Aging (Albany NY)       Date:  2021-08-12       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.